Mayo Foundation for Medical Education and Research

US Government as Represented by the Secretary of the Army

The Hong Kong University of Science and Technology

U.S. Army Medical Research and Material Command

Yuan-Ping Pang

Elliott Richelson

Abdul H Fauq

Daniel J McCormick

Bernadette Marie Cusack

Beth Marie Tyler

Mona Boules

Jewn Giew Park

Stephen Brimijoin

James J Schmidt

Charles B Millard

Andrew Badley

Paul Carlier

Scott H Kaufmann

Rajesh K Mishra

Jing Tang

Shaohua Wang

Anuradha Vummenthala

Jon Davis

Da-Ming Du

Yifan Han

Amy M Nguyen

Haiming Dai

This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.

Method for killing HIV-infected cells using Bcl-2 inhibitors

Small-molecule inhibitors of Botulinum toxin, including BoNTA, BoNTD and BoNTE are provided, as well as methods of using the inhibitors.

Small-molecule botulinum toxin inhibitors

This disclosure relates to materials and methods for inhibiting Botulinum neurotoxin, and more particularly to materials and methods for inhibiting the zinc endopeptidase of Botulinum neurotoxin serotypes A, D and/or E (BoNTA, BoNTD and/or BoNTE).

A method for designing a metal ion for use in a molecular dynamics simulation can include the steps of building a metal ion molecule having a center atom and a dummy atom, assigning a van der Waals radius to the center atom, and assigning a charge to the dummy atom. A metal ion molecule may have the center atom covalently linked to one or more dummy atoms resulting in the metal ion molecule having a polyhedron geometry. New force field parameters may be used in methods for designing metal ions for use in molecular dynamics simulations.

Molecular modeling for metalloproteins

The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.

Neo-tryptophan

Disclosed are efficient methods for loading amino derivatives onto trityl chloride resins and for cleaving chemically modified amino derivatives from trityl chloride resins. Methods for making a library of discrete chemically modified amino derivatives also disclosed.

Efficient methods for solid phase synthesis using trityl chloride resins

The invention relates to dimeric compounds comprising two 5-amino-5,6,7,8-tetrahydroquinoline fragments joined together by a divalent linking group, processes for their preparation, intermediates for their preparation, pharmaceutical compositions containing such dimeric compounds and the use of such compounds as cholinesterase inhibitors and in the treatment of neurodegenerative diseases, such as Alzheimer's Disease and myasthenia gravis.

Dimeric compounds

Bifunctional acetylcholinesterase reactivators

The present invention provides cholinesterase inhibitors of general formula (I): ##STR1## wherein R is H or (C.sub.1 -C.sub.4)alkyl, Y is a linking group and Z is an aryl group, and the pharmaceutically acceptable salts thereof.

THA analogs useful as cholinesterase inhibitors

The present invention provides cholinesterase inhibitors of general formula (I): ##STR1## wherein R is H or (C.sub.1 -C.sub.4)alkyl, Y is a linking group and Z is an alkyl or aryl group, including heteroaryl groups, and the pharmaceutically acceptable salts thereof.

Growing community of inventors

Rochester, MN, United States of America

Yuan-Ping Pang